NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-FL(FITC-E2) CAR-T cells
A preparation of genetically modified T cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a second generation chimeric antigen receptor (CAR) consisting of an anti-fluorescein (anti-FL) fluorescein isothiocyanate (FITC)-E2 single chain variable fragment (scFv), that is coupled, via an immunoglobulin G4 (IgG4) hinge-CH2(L295D)-CH3 spacer, to the costimulatory signaling molecules CD28, CD137 (4-1BB), and CD3 zeta, and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Prior to the administration of anti-FL(FITC-E2) CAR-T cells, the CAR-T adaptor molecule (CAM) EC17 is administered. EC17 is a bispecific molecule that is composed of folic acid conjugated to FITC (folate-FITC). EC17 targets and binds with its folate moiety with high affinity to folate receptor (FR)-expressing tumor cells. Upon administration of the anti-FL(FITC-E2) CAR-T cells, these cells are attracted by and bind to the FITC antigen moiety of EC17. Upon binding to EC17, the T cells induce specific tumor cell lysis, cytokine secretion, and proliferation, and activate a robust immune response against the EC17-bound, FR-expressing tumor cells. FR is overexpressed in various tumor cell types and is associated with increased leukemic cell proliferation and aggressiveness. The co-stimulatory molecules are required for full T-cell activation and enhance both proliferation of T cells and antitumor activity. EGFRt both facilitates detection of the administered T cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The reactivity of the anti-FL(FITC-E2) CAR-T cells is dependent on dosing of EC17, and therefore allows CAR-T-cell activity to be controlled by dosing of EC17. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:antiFL(FITCE2) CAR expressing T cells
anti-FL(FITCE2) CAR expressing T cells
anti-FL(FITC-E2) CAR T lymphocytes
fluorescein-specific (FITC-E2)-CAR T cells